📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-18 11:57
161 analysed today
FollowTelegram
161
Today
149,562
All-time analysed
42,894
Positive
6,654
Negative
91,341
Neutral
8,605
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
11 announcements match the current filters (relevance ≥ 5).
Haleos Labs Clears USFDA Inspection with Zero Form 483 Observations at Mahi Drugs Unit
The USFDA successfully completed an inspection of Mahi Drugs Private Limited, a material subsidiary of Haleos Labs Limited, from September 15 to September 18, 2026. The inspection concluded with zero Form 483 observations, replicating the clean outcome of the previous inspection in January 2025. This facility is located at Jawaharlal Nehru Pharma City, Parawada, Andhra Pradesh, and produces active pharmaceutical ingredients (APIs). A zero-observation outcome reduces compliance uncertainty and supports the company's US-focused supply plans against its TTM revenue base of Rs 332 Cr.
Confidence: HIGH
What changedUSFDA concluded its audit of Mahi Drugs Private Limited with zero observations, confirming ongoing GMP compliance.
Why it mattersA clean USFDA inspection removes regulatory risks of import alerts or warning letters, safeguarding exports to the lucrative US market.
Form 483 Observations: 0Inspection Period: September 15, 2026 to September 18, 2026Previous Inspection Date: January 24, 2025TTM Revenue Context: Rs 332 Cr
📅 Short termPositive sentiment driver as regulatory overhang from an active audit is cleared without any compliance remedial actions required.
📈 Long termReaffirms the company's US compliance status, enabling continued API supply and potential new DMF filings to support its 50+ product target by FY2028.
⚠ Risk flags
- Formal Establishment Inspection Report (EIR) issuance remains the final administrative closure step.
Key Highlights
Inspection concluded with zero Form 483 observations
Inspection conducted from September 15, 2026 to September 18, 2026
Replicates the zero-observation outcome from the January 2025 USFDA audit
Site: API facility of material subsidiary Mahi Drugs Private Limited at Parawada, Andhra Pradesh
👀 What to Watch
Track the formal receipt of the Establishment Inspection Report (EIR) from the USFDA and subsequent product launch or export traction from this facility in regulated markets.
Haleos Labs Appoints ChemWerth President Vincent P. Asaro as Nominee Director for Mahi Drugs
Haleos Labs Limited has announced key changes at its material subsidiary, Mahi Drugs Private Limited, effective August 5, 2026. Mr. Vincent P. Asaro, the President of ChemWerth Inc. (a global API developer), has been appointed as a Nominee Director, replacing Mr. M. Madhu Rao. This appointment brings over 35 years of international pharmaceutical and financial expertise to the subsidiary's board. Additionally, Annapragada & Co. has been appointed as the Cost Auditor for the subsidiary for the 2026-27 financial year.
Confidence: HIGH
What changedThe material subsidiary Mahi Drugs has replaced its Nominee Director with the President of its global partner ChemWerth Inc. and appointed new cost auditors.
Why it mattersHaving the head of a global API supplier on the board of a material subsidiary strengthens strategic ties and provides high-level expertise for navigating regulated international markets, which is critical for Haleos' goal of reaching 50+ products by FY2028.
Director Experience: 35 yearsCost Audit Period: FY 2026-27TTM Revenue: Rs 348 CrMarket Cap: Rs 507 Cr
📅 Short termThe appointment is likely to be viewed positively by the market as it signals professionalization and stronger global linkages for the subsidiary.
📈 Long termThis move supports the company's structural shift toward complex, niche APIs and regulated market expansion by leveraging ChemWerth's global presence.
Key Highlights
Appointment of Mr. Vincent P. Asaro as Nominee Director effective August 5, 2026
Mr. Asaro brings over 35 years of experience in finance, corporate strategy, and pharmaceutical operations
ChemWerth Inc., where Mr. Asaro is President, is a leading global developer and supplier of APIs to regulated markets
Annapragada & Co. appointed as Cost Auditors for the material subsidiary for FY 2026-27
Haleos Labs maintains a market capitalization of Rs 507 Cr with TTM revenue of Rs 348 Cr
👀 What to Watch
Investors should monitor if this board-level alignment with ChemWerth leads to increased order flow or faster approvals in regulated markets like the USA and Brazil, which are key parts of the company's FY2028 growth strategy.
Haleos Labs Q1 FY27: Net Profit Drops 36% YoY to ₹2.65 Cr on 11.6% Revenue Decline
Haleos Labs Limited (formerly SMS Lifesciences) reported a weak set of consolidated results for Q1 FY27. Revenue from operations declined 11.6% YoY to ₹72.94 Cr, while net profit attributable to the parent fell 36.3% YoY to ₹2.65 Cr. The decline is notable as cost of materials consumed rose to ₹40.14 Cr from ₹27.73 Cr in the year-ago period, despite the lower topline, indicating significant margin pressure. On a sequential basis, profit improved from a very low base of ₹0.44 Cr in Q4 FY26, but remains well below historical averages.
Confidence: HIGH
What changedThe company has transitioned from a period of higher profitability to one of margin compression, with a double-digit decline in revenue and a significant spike in raw material costs as a percentage of sales.
Why it mattersAs a global leader in Ranitidine Hcl, the company's high product concentration makes it vulnerable to pricing and demand shifts; these results suggest a challenging environment for its core API portfolio.
Consolidated Revenue (Q1 FY27): ₹72.94 CrNet Profit (Attributable to Parent): ₹2.65 CrYoY Revenue Growth: -11.6%YoY PAT Growth: -36.3%EPS (Q1 FY27): ₹8.75Revenue vs TTM Revenue: ~21%
📅 Short termThe stock may face downward pressure in the short term as the market reacts to the YoY contraction in both scale and profitability.
📈 Long termThe long-term outlook depends on the successful execution of backward integration and expansion into niche APIs to mitigate the current high concentration risk and margin volatility.
⚠ Risk flags
- High product concentration (Ranitidine Hcl)
- Significant increase in raw material costs
- Fragmented industry pricing pressure
Key Highlights
Consolidated Revenue from Operations fell 11.6% YoY to ₹72.94 Cr from ₹82.50 Cr.
Net Profit attributable to the parent decreased 36.3% YoY to ₹2.65 Cr from ₹4.16 Cr.
Consolidated EPS for the quarter stood at ₹8.75, down from ₹13.75 in Q1 FY26.
Cost of materials consumed increased to ₹40.14 Cr, representing 55% of revenue vs 33.6% in the year-ago quarter.
Board approved the re-appointment of two Independent Directors for a second 5-year term starting November 2026.
👀 What to Watch
Investors should monitor the company's ability to pass on rising raw material costs and track the progress of its product diversification strategy, aiming for 50+ products by FY2028 to reduce reliance on Ranitidine Hcl.
Haleos Labs Promoters Declare Zero Encumbrance of Shares for FY 2025-26
TVVSN Murthy, representing the promoter and promoter group of Haleos Labs Limited, has filed an annual disclosure under Regulation 31(4) of SEBI SAST Regulations. The declaration confirms that no shares held by the promoter group were encumbered or pledged, directly or indirectly, during the financial year ended March 31, 2026. The disclosure lists 15 promoter entities, including major shareholders like Hima Bindu Potluri (7,42,436 shares) and TVVSN Murthy (4,80,034 shares). This filing serves as a confirmation of the financial stability of the promoters regarding their equity holdings.
Key Highlights
Promoter group confirms zero shares are pledged or encumbered as of the year ended March 31, 2026.
Compliance filing made under Regulation 31(4) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.
Major individual holdings disclosed include Hima Bindu Potluri (7,42,436 shares) and TVVSN Murthy (4,80,034 shares).
Other significant promoter holdings include Rajeswara Rao Gopineedi with 2,73,939 shares and Ramesh Babu Potluri with 2,40,190 shares.
A total of 15 promoter and promoter group entities are covered under this non-encumbrance declaration.
👀 What to Watch
Investors can take comfort in the fact that there is zero promoter pledge, which reduces the risk of forced selling during market volatility. No immediate action is required as this is a routine annual regulatory disclosure.
Haleos Labs Recommends Rs 1.50 Dividend; FY26 Net Profit Declines 16.8% YoY
Haleos Labs Limited has recommended a final dividend of Rs 1.50 (15%) per equity share for FY2025-26. The company's annual standalone revenue declined to Rs 300.99 crore from Rs 333.37 crore in the previous year. Net profit for the full year also saw a contraction, falling to Rs 17.78 crore from Rs 21.37 crore. Alongside results, the company announced the resignation of an independent director and the reappointment of a Whole-time Director for five years.
Key Highlights
Recommended a final dividend of Rs 1.50 per equity share of Rs 10 face value.
Annual standalone revenue decreased by 9.7% YoY to Rs 30,098.96 Lakhs.
Standalone Net Profit for FY26 fell to Rs 1,777.68 Lakhs compared to Rs 2,137.08 Lakhs in FY25.
Q4 FY26 revenue dropped significantly to Rs 6,338.42 Lakhs from Rs 8,542.78 Lakhs in the year-ago quarter.
Earnings Per Share (EPS) for the full year decreased to Rs 58.80 from Rs 70.69.
👀 What to Watch
Investors should exercise caution as the dividend payout comes amid declining revenue and profitability. Monitor the company's ability to arrest the top-line slide and the impact of the upcoming statutory auditor change.
Haleos Labs FY26 Revenue Drops 9.7% to ₹301 Cr; Recommends ₹1.50 Dividend
Haleos Labs reported a decline in its financial performance for the fiscal year ended March 31, 2026, with annual revenue dropping to ₹300.99 crore from ₹333.37 crore in the previous year. Net profit for the full year also saw a contraction, falling to ₹17.78 crore compared to ₹21.37 crore in FY25. Despite the lower earnings, the board has recommended a dividend of ₹1.50 per equity share (15% of face value). The company also announced the reappointment of Mrs. Sudeepthi Gopineedi as Whole-time Director for five years.
Key Highlights
Annual Revenue from Operations decreased by 9.7% YoY to ₹30,098.96 Lakhs in FY26.
Net Profit for FY26 fell by 16.8% to ₹1,777.68 Lakhs from ₹2,137.08 Lakhs in FY25.
Board recommended a dividend of ₹1.50 per equity share (15%) for the financial year 2025-26.
Q4 FY26 Revenue stood at ₹6,338.42 Lakhs, a significant drop from ₹8,542.78 Lakhs in the year-ago quarter.
Mrs. Sudeepthi Gopineedi reappointed as Whole-time Director for 5 years effective Sept 2, 2026.
👀 What to Watch
The decline in both top-line and bottom-line performance is concerning; investors should wait for management commentary on margin pressures. The dividend provides a small yield, but the focus should remain on the company's ability to reverse the revenue slide.
Haleos Labs Credit Rating Reaffirmed at IVR BBB/Positive; Rated Facilities Enhanced to ₹116 Cr
Infomerics Valuation and Rating Limited has reaffirmed the credit ratings for Haleos Labs Limited and its material subsidiary, Mahi Drugs Private Limited. The company's long-term rating is maintained at IVR BBB with a 'Positive' outlook, while the short-term rating remains IVR A3+. Significantly, the total rated bank loan facilities for the parent company have been enhanced from ₹81.86 crore to ₹116.01 crore, indicating increased borrowing capacity for operations or expansion.
Key Highlights
Long-term rating reaffirmed at IVR BBB with a 'Positive' outlook for Haleos Labs Limited.
Short-term rating reaffirmed at IVR A3+ for fund-based and non-fund based bank facilities.
Total rated bank loan facilities for the company increased from ₹81.86 crore to ₹116.01 crore.
Material subsidiary Mahi Drugs Private Limited's rated facilities enhanced to ₹20.75 crore with IVR BB+/Stable rating.
Ratings assessment included operational and financial performance data up to 9MFY26.
👀 What to Watch
The 'Positive' outlook indicates a potential for a rating upgrade in the medium term if financial performance stays robust. Investors should monitor the company's ability to service the increased debt levels as it utilizes the enhanced bank facilities.
Haleos Labs Seeks Approval for ₹20 Crore Corporate Guarantee for Subsidiary Mahi Drugs
Haleos Labs Limited has issued a postal ballot notice to seek shareholder approval for a material related party transaction. The company intends to provide a corporate guarantee of up to USD 2.2 million (approximately ₹20 crores) in favor of RBL Bank. This guarantee is required to secure an External Commercial Borrowing (ECB) facility for its subsidiary, Mahi Drugs Private Limited. Shareholders can cast their votes via remote e-voting between March 31 and April 29, 2026.
Key Highlights
Proposed corporate guarantee of USD 2.2 million (approx. ₹20 crores) for subsidiary Mahi Drugs Private Limited
Guarantee to secure External Commercial Borrowing (ECB) facility from RBL Bank
Shareholder approval sought via postal ballot through remote e-voting process
E-voting period scheduled from March 31, 2026, to April 29, 2026
Final results of the postal ballot to be declared on May 1, 2026
👀 What to Watch
Investors should monitor the parent company's contingent liabilities and the performance of Mahi Drugs to ensure the debt is well-serviced. This move indicates financial support for subsidiary expansion but increases the parent's risk profile.
Haleos Labs Seeks Shareholder Approval for Corporate Guarantee to Subsidiary Mahi Drugs
Haleos Labs Limited has initiated a Postal Ballot process to seek shareholder approval for a material related party transaction. The company intends to provide a corporate guarantee to RBL Bank to secure External Corporate Borrowing (ECB) facilities for its subsidiary, Mahi Drugs Private Limited. The e-voting period is scheduled to run from March 31, 2026, to April 29, 2026, with final results to be declared on May 1, 2026. This move highlights the parent company's financial support for its subsidiary's capital requirements.
Key Highlights
Proposed ordinary resolution for a corporate guarantee to RBL Bank for subsidiary Mahi Drugs Private Limited.
The transaction is categorized as a Material Related Party Transaction under SEBI regulations.
Cut-off date for shareholder voting eligibility is March 27, 2026.
E-voting window is open for 30 days from March 31 to April 29, 2026.
Postal ballot results will be officially declared on May 1, 2026.
👀 What to Watch
Investors should evaluate the financial health of the subsidiary, Mahi Drugs, as this guarantee increases the contingent liabilities of Haleos Labs. Monitor the final voting results on May 1 to confirm the approval of this financial arrangement.
Haleos Labs Q3 FY26 Consolidated Net Profit Rises 37% YoY to ₹6.65 Cr; Revenue Up 12%
Haleos Labs Limited (formerly SMS Lifesciences) reported a strong consolidated performance for Q3 FY26, with revenue growing 12% YoY to ₹94.78 crore. Consolidated net profit surged 37% YoY to ₹6.65 crore, driven by improved operational efficiencies and lower finance costs. The board also approved a corporate guarantee for its subsidiary, Mahi Drugs, to facilitate External Commercial Borrowing (ECB), indicating potential expansion plans. While standalone revenue saw a slight dip, the consolidated numbers reflect robust growth from subsidiary operations.
Key Highlights
Consolidated Revenue from Operations increased 12% YoY to ₹94.78 crore from ₹84.60 crore.
Consolidated Net Profit grew 37% YoY to ₹6.65 crore compared to ₹4.85 crore in Q3 FY25.
Consolidated EPS rose to ₹21.89 for the quarter, up from ₹18.08 in the corresponding previous year quarter.
Finance costs on a consolidated basis decreased to ₹1.54 crore from ₹2.14 crore YoY.
Board approved a corporate guarantee for subsidiary Mahi Drugs for External Commercial Borrowing, subject to shareholder approval.
👀 What to Watch
Investors should view the strong consolidated profit growth and debt reduction in finance costs as positive indicators. Monitor the upcoming postal ballot regarding the corporate guarantee for Mahi Drugs as it signals future capital expenditure or expansion.
Haleos Labs Partners with HRV Global for Orphan Drug and Niche API Manufacturing
Haleos Labs Limited has entered into a strategic development collaboration with HRV Global Life Sciences to accelerate the manufacturing of orphan drugs and niche therapeutic APIs. The partnership combines Haleos' USFDA-GMP aligned manufacturing expertise with HRV Global's international regulatory and market access capabilities. This initiative targets high-value, underserved therapeutic segments in major regulated markets including the US and EU. The collaboration is designed to strengthen the company's global footprint across Latin America, MENA, and APAC regions through coordinated development pathways.
Key Highlights
Strategic collaboration with HRV Global Life Sciences for orphan drug and niche therapeutic APIs
Leverages Haleos' USFDA-GMP manufacturing systems for high-value complex molecules
Targets expansion into regulated and semi-regulated markets including US, EU, and Latin America
Focuses on underserved therapeutic segments to improve product mix and margins
HRV Global to lead regulatory execution and global market access initiatives
👀 What to Watch
Investors should view this as a positive move toward high-margin niche segments; monitor for specific product pipeline updates and regulatory filings in the US and EU markets.
